Small nonphosphorylated Grb2-SH2 domain antagonists evaluated by surface plasmon resonance technology

The growth factor receptor‐binding protein–Src homology 2 (Grb2–SH2) domain plays an important role in the oncogenic Ras signal transduction pathway, which involves cell proliferation and differentiation. Therefore, the Grb2–SH2 domain has been chosen as our target for development of potential antip...

Full description

Saved in:
Bibliographic Details
Published in:Biopolymers 2005, Vol.80 (5), p.628-635
Main Authors: Lung, Feng-Di T., Chang, Chiung-Wen, Chong, Meng-Chin, Liou, Chien-Chung, Li, Peng, Peach, Megan L., Nicklaus, Marc C., Lou, Bih-Show, Roller, Peter P.
Format: Article
Language:English
Subjects:
BIACORE X
Drug Evaluation, Preclinical
Fluorenes - chemical synthesis
Fluorenes - chemistry
Fluorenes - pharmacology
Grb2
Models, Molecular
Molecular Conformation
peptides
Peptides - chemical synthesis
Peptides - chemistry
Peptides - pharmacology
Phosphorylation
Ras
SH2 domain
signal transduction pathway
src Homology Domains - drug effects
src Homology Domains - physiology
Structure-Activity Relationship
surface plasmon resonance
Surface Plasmon Resonance - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The growth factor receptor‐binding protein–Src homology 2 (Grb2–SH2) domain plays an important role in the oncogenic Ras signal transduction pathway, which involves cell proliferation and differentiation. Therefore, the Grb2–SH2 domain has been chosen as our target for development of potential antiproliferative agents. Herein, we report the study of the inhibitory effects of small nonphosphorylated peptide analogs interacting with the Grb2–SH2 domain protein by surface plasmon resonance (SPR) technology. A set of 8 related peptide analogs were synthesized, purified, and characterized. Their inhibitory effects on Grb2–SH2 were evaluated by the SPR technology developed with the BIACORE X instrument. The lead peptide, Fmoc–Glu–Tyr–Aib–Asn–NH2 (Fmoc–E–Y–Aib–N; Fmoc: 9‐fluorenylmethyoxycarbonyl; Aib = α‐amino isobutyric acid) inhibited Grb2–SH2 domain function with an IC50 value of 8.7 μM. A molecular modeling study of the lead peptide indicated that the glutamate in the Fmoc peptide is ideally positioned to form a strong salt bridge to Arg 67 in the Grb2–SH2 domain, using both its backbone carbonyl and its acidic group. Residue Glu 89 in Grb2–SH2 flips inward to fill the binding site and partially replace the phosphate group as a hydrogen‐bond acceptor. Results of these studies provide important information for further development of potent nonphosphorylated peptide inhibitors of the Grb2–SH2 domain. © 2005 Wiley Periodicals, Inc. Biopolymers (Pept Sci), 2005
ISSN:0006-3525
1097-0282
DOI:10.1002/bip.20209